GLP-1 drugs, such as Lixisenatide, are showing promise in slowing down the progression of Parkinson's disease symptoms. Studies indicate that these drugs may have neuroprotective effects and could potentially be disease-modifying in early Parkinson's disease. French researchers observed significant symptom deceleration in a year-long trial involving 156 participants compared to those on a placebo. The medication has been associated with less progression of motor disability and reduced motor disability over a 12-month period in persons with Parkinson's disease.
Lixisenatide, a glucagon-like peptide-1 receptor agonist, demonstrated neuroprotective effects in Parkinson’s disease models. A phase 2 trial explored its impact on motor disability progression in early Parkinson’s patients. Subjects received daily subcutaneous lixisenatide or…
In a placebo-controlled LIXIPARK trial involving persons with Parkinson’s disease, the subcutaneous GLP-1 receptor agonist lixisenatide was associated with reduced motor disability over a period of 12 months. Full trial results and Research Summary: https://t.co/2ancdAqO9i https://t.co/69h3la4AA0
While the world watches the expanding translational relevance of GLP-1 medicines, @AcquiredFMsat down to discuss the history of scientific GLP-1 drug development and innovation with @lotte_bjerre @novonordisk #T2D #obesity #Liraglutide #Semaglutide https://t.co/KHkVLj9xJ7 https://t.co/wIFjVNjP8h
A Type 2 diabetes medication called lixisenatide appeared to slow the progression of #Parkinsons disease symptoms in a small, mid-stage trial https://t.co/O9Xc07Ka7c
"In participants with early Parkinson’s disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects." https://t.co/ZWTetHVahG
Lixisenatide, a glucagon-like peptide-1 receptor agonist used to treat type 2 diabetes, is under study as a potential treatment for Parkinson’s disease. Research findings are summarized in a new Quick Take video. https://t.co/bDm7VX9eec https://t.co/2sgfhu4zAL
It has been a big week for the GLP-1 drugs. In the new Ground Truths (link in profile): —Rundown of new randomized trials in #Parkinsons disease and heart disease —An explainer podcast with @DanielJDrucker, co-discoverer of GLP-1 https://t.co/yWwQMcsI8X
Ozempic-Like Drug Slowed Progression of Parkinson's Disease in New Trial https://t.co/K5zz1cg0HL
GLP1Ra has shown protective effects in a murine model of Parkinson’s. In a trial of 156 with recently diagnosed PD, GLP1Ra (lixisenatide) prevented the progression of disability https://t.co/Gn0pbRIT2Y @NEJM https://t.co/wU3vdIeISn
🚨STUDY: OZEMPIC SLOWS PARKINSON'S? A study unveils that Lixisenatide, related to diabetes drug Ozempic, may slow Parkinson's disease. French researchers observed significant symptom deceleration in a year-long trial involving 156 participants compared to those on a placebo.… https://t.co/J3Q3oHklEF
🚨STUDY: OZEMPIC RELATIVE SLOWS PARKINSON'S A study unveils that Lixisenatide, related to diabetes drug Ozempic, may slow Parkinson's disease. French researchers observed significant symptom deceleration in a year-long trial involving 156 participants compared to those on a… https://t.co/kypw3o68z4
A medication used to treat diabetes slowed the progression of motor issues associated with #Parkinson's disease. https://t.co/wMnLhCtJr5
Original Article: Trial of Lixisenatide in Early Parkinson’s Disease (LIXIPARK phase 2 trial) https://t.co/2ancdAqO9i Editorial: GLP-1, Parkinson’s Disease, and Neuroprotection https://t.co/ZaFfYyvEP9 #Neurology https://t.co/h6Ds5wVSHu
Join us in Boston for a forward-looking conversation exploring the transformative ripple effects of GLP-1s at our #STATOpenDoors event next week. Learn more: https://t.co/9T0BveRFFW
#GLP1 -agonist Lixisenatide promising neuroprotective effects shown in pre-clinical trial in Early Parkinson’s Disease | New England Journal of Medicine. https://t.co/0oq8bt61FF
Could the GLP-1 drug lixisenatide be disease modifying in Parkinson disease? https://t.co/LuvkgPYfD0 @NEJM #NeuroTwitter #Parkinsons https://t.co/Xbw4uBMRDl
A GLP-1 medication from French drugmaker Sanofi — similar to Ozempic — was found to slow Parkinson’s in a small mid-stage trial. https://t.co/9Lvkufounw
A new study finds GLP-1 drugs may be used to slow down Parkinson's disease. "If you're talking to someone that has Parkinson's and you can talk about slowing these symptoms down at least 12 months, that's an incredible amount of quality of life for them," says @kavitapmd: https://t.co/yfNXxQelmR
The Breakthrough of the Year @AAAS Bhaumik Prize goes to the 2 scientists who pushed/fought to get GLP-1 drugs to treat obesity (which took decades!) https://t.co/EFAB5pczbd by @MeaganPhelan, with the whole, fascinating story pleased to be a member of the selection committee https://t.co/3vaGFGgzPg
A diabetes drug related to the latest generation of obesity drugs can slow the development of the symptoms of Parkinson’s disease https://t.co/cvXi4LtNzt
Trial of Lixisenatide in Early Parkinson’s Disease https://t.co/THoEco8r9F https://t.co/nryIfm0fW4
GLP-1 drugs are showing early potential to help people with Parkinson’s disease, according to new study results. https://t.co/d41ZKpFs9S